74	

6. The compound according to claim 5, wherein the compound is selected from the group consisting of compounds 1, 2, 18, 24, 25, 31, 32, 60 and 61.

7. The compound according to claim 5, wherein the compound is selected from the group consisting of compounds 3, 5, 6, 7, 8, 9, 10, 12, 15, 26, 29, 34, 37, 40, 49 and 51.

8. The compound according to claim 5, wherein the compound is selected from the group consisting of compounds 14, 16, 17, 20, 21, 23, 30, 33, 36, 39, 41, 44, 45, 46, 47, 50, 55, 57, 58, 59, 62, 63, 64, 66, 67, 68, 69, 72 and 73.

9. The compound according to claim 5, wherein the compound is selected from the group consisting of compounds 11, 13, 19, 27, 28, 35, 43, 48, 54, 56 and 74.

10. A pharmaceutical composition comprising a compound of any one of claims 1 to 9 and a pharmaceutically acceptable carrier or diluent.

11. ~~A method of modulating the target kinase function comprising administering~~ Use of a compound of any one of claims 1 to 9 or a pharmaceutical composition of claim 10 in the manufacture of a medicament for modulating the target kinase function.

12. The ~~method~~ use according to claim 11, wherein the target kinase function is a a function of kinase selected from the PDGFR, FGFR, VEGFR.

13. The ~~method~~ use accordign to claim 12, wherein the the kinase is cFMS, Flt3, KDR, FGFR1 or Tie2.

14. A ~~use of a~~ compound of any one of claims 1 to 9 for use as an inhibitor of a protein kinase .

15. The ~~use~~ compound according to claim 14, wherein the protein kinase is selected from the group consisting of PDGFR, FGFR and VEGFR.

16. The ~~use~~ compound according to claim 14, wherein the protein kinase is selected from the group consisting of cFMS, Flt3, KDR, FGFR1 or Tie2.

17. A prope comprising a compound of any one of claims 1 to 9 and a detectable label or affinity tag for said compound.

18. The probe according to claim 17, wherein the detectable label is selected from a fluorescent moiety, a chemiluminescent moiety, a paramagnetic contrast agent, a metal chelate, a radioactive isotope-containing moiety, and biotin.

19. ~~A method of modulating target kinase fuction comprising contacting a cell with~~Use of a compound of any one of claims 1 to 9 in a manufacture of a medicament for modulating target kinase fuction, wherein the medicament is to be contacted to a cell in an amount sufficient to modulate the target kinase function, whereby the target kinase activity and signaling is modulated.

20. A process for preparing a compound of formula i-e, comprising the steps of:

(a) alkylation of R^1NH_2 with bromoacetonitrile to provide intermediate i-a



i-a